Cognition Therapeutics, Inc.

4:45 PM - 5:00 PM, Tuesday, June 4, 2019 ・ Theater 3
Cognition Therapeutics, Inc., a privately held biopharmaceutical company, is focused on the development of a pipeline of disease-modifying small molecule drug candidates that are designed to normalize the impaired membrane trafficking pathways that are the root cause of many CNS disorders. By so doing, Cognition’s drug candidates aim to protect and restore synaptic function, thereby preserving brain health. The Company's lead candidate, Elayta™, is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer's disease. Cognition’s three ongoing clinical trials – SPARC, SNAP and SHINE – are supported by grants from the National Institute on Aging.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
Elayta
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
President and Chief Executive Officer
Cognition Therapeutics